Skip to content 
A Multi-arm Clinical Trial Accelerator and Derisking Platform for Parkinson’s Disease (PD)
PD is the fastest growing neurological condition worldwide, with..
WHY SO MANY TRIALS FAIL?
Despite numerous completed clinical trials, we still lack disease modifying therapies that can slow or halt the progression of Parkinson’s disease. A major reason is that many candidate drugs advance into late-stage trials without solid evidence that they engage their biological targets. As a result, large and costly trials often fail, delaying progress toward effective treatments.
SLEIPNIR:
AN INNOVATIVE APPROACH
SLEIPNIR directly addresses this gap. The platform is designed to determine early whether a potential disease-modifying therapy penetrates the central nervous system (CNS) and acts on its intended target. By filtering out ineffective compounds early, SLEIPNIR enables a smarter, faster, and more efficient pathway to treatment development for Parkinson’s disease, focusing resources only on the treatments with the highest likelihood of success.
DESIGN
SLEIPNIR is a Phase 2a, randomized, double-blind, biomarker-driven, multi-arm platform trial designed to test several potential disease-modifying treatments for Parkinson’s disease in parallel. Each treatment is evaluated in its own cohort, but all cohorts share a common trial infrastructure and, when scientifically valid, a pooled contemporary placebo group.
The platform uses a two-step randomization process:
1. Randomization across active cohorts that are open at the same time.
2. Randomization within each cohort to either active treatment or matching placebo.
Because only contemporary placebo participants are used for comparison, the allocation ratio (active:placebo) may differ between cohorts to ensure sufficient control numbers and scientific validity.
Each participant undergoes:
· Up to 8 weeks of screening, including optimization of standard of care medication.
· 12 weeks of treatment with either an investigational compound or placebo.
· 4 weeks of safety follow-up after the last dose.
All participants provide CSF and blood samples and undergo brain imaging to measure:
· CNS penetration of the compound (via CSF-to-plasma ratios)
· Target engagement in the CNS (compound-specific biomarkers)
SLEIPNIR is non-adaptive: all study arms run to completion unless stopped for safety reasons. New compounds can enter the platform asynchronously, allowing rapid evaluation of emerging therapeutic candidates.
Only treatments that demonstrate acceptable safety, robust CNS penetration, and clear evidence of target engagement will be recommended for advancement into later-phase efficacy trials
OBJECTIVES
Safety: To evaluate the safety and tolerability of each investigational compound
CNS penetration: To determine whether each compound enters the human brain, measured by CSF-to-plasma concentration ratios of the parent drug and/or relevant metabolites at steady state.
Target engagement: To assess whether each compound acts on its intended biological target within the CNS. This is evaluated using compound-specific biomarkers in CSF (and supportive blood/imaging markers), reflecting the expected molecular or biochemical effect of the treatment in the brain.
